IFNA1 and respiratory tract infectious disorder: Among these, a frameshift mutation in the promoter of IFNL4 results in the loss of IFN-λ4 production and concomitant improved clearance of HCV as well as other gastrointestinal and respiratory infections though the mechanism by which the loss of an IFN results in an improved antiviral response remains unclear (51, 52).